Acid β-glucosidase (GBA1) gene mutational spectrum and clinical phenotypes in patients with gaucher disease: seven novel mutations in a multicenter retrospective cohort study from upper Egypt
- Open Access
- 01.12.2025
- Research
Erschienen in:
Abstract
Introduction
Gaucher disease (GD) is one of the most common autosomal recessive lysosomal storage diseases caused by variants in the acid β-glucosidase (GBA1) gene, which encodes the glucocerebrosidase enzyme [1]. Deficiency of enzymatic activity leads to progressive glucocerebrosidase accumulation, primarily in the mononuclear phagocyte system, within macrophages [2]. GD is a multisystemic disease with heterogeneous phenotypes; however, it is clinically classified into three types based on age of onset, neurological involvement, and disease progression [3]. Type 1 (non-neuronopathic) is the most common subtype and presents with early onset of symptoms, hematological involvement, hepatosplenomegaly, and skeletal manifestations. Type 2 GD (acute neuronopathic) is the most serious subtype and presents in early infancy with rapid brain deterioration. Type 3 GD (chronic neuronopathic) is a subacute form where clinical expressions start in childhood and adolescence [3, 4].
The GBA1 gene, located on chromosome 1q22, has a highly homologous pseudogene sequence. Thus, variant detection is not easy, and amplification primers are required to discriminate between the functional gene and the pseudogene. More than 721 different GBA1 gene variants have been reported in GD [5]. Numerous variants have been associated with specific clinical characteristics; however, genotype-phenotype correlation is characterized by variable expression and appearance in different individuals and ethnic groups. The most frequent variants in GD patients are c.1226 A > G p.(Asn409Ser) and c.1448T > C p.(Leu483Pro) [6]. The most frequent variant recognized in Romanian patients is p.(Asn409Ser) [7], while c.1226 A > G p.(Asn409Ser) and c.1448T > C p.(Leu483Pro) are common in Spain [6]. In Ashkenazi Jewish patients, the p.(Asn409Ser) variant, along with c.84dupG (84GG) and IVS2 + 1G > A, represent approximately 96% of variants, whereas in non-Jewish patients these three account for 50–60% of variants [8]. In Caucasian patients, 60–70% of variants are c.1226 A > G p.(Asn409Ser), c.1448T > C p.(Leu483Pro), and c.1342G > C p.(Asp448His) [8].
Anzeige
Thus, c.1226 A > G p.(Asn409Ser) variant has not been associated with neurological involvement and is usually found in type 1 GD. The c.1448T > C p.(Leu483Pro) variant is associated with neurological manifestations and typically allied with type 2 or type 3 GD, even in the heterozygous form [6, 8]. Moreover, the c.680 A > G p.(Asn227Ser) and c.1180G > T p.(Val394Leu) alleles are linked to type 3 GD, accompanied by myoclonic epilepsy [9]. This study was designed to identify variants in Egyptian GD patients living in an area of high consanguinity and correlate their genotypes with clinical characteristics.
Methodology
Patients
This descriptive study was carried out in the Hematology Unit of Assiut University Children’s Hospital in Egypt and the Genetics Department of Ain Shams University. The study involved 68 Egyptian patients with GD and was approved by the Ethics and Research Committee of the Faculty of Medicine, Assiut University (approval number: 04-2023-300227). All participants signed consent forms. All recruited patients were diagnosed with GD based on reduced β-glucocerebrosidase activity and was confirmed by GBA1 genotyping.
Data collection
All enrolled patients underwent a thorough medical history assessment, including the duration of their illness and relevant family history. Clinical and laboratory information at presentation was gathered from patient records, including the age of presentation. All patients underwent a comprehensive clinical examination, including weight and height assessment, evaluation of liver and spleen size (both clinically and by ultrasound), and an ophthalmological examination. Neurological evaluations were conducted by a neurologist. GD type was categorized clinically by the treating physicians. Type 1 GD (chronic non-neuronopathic subtype) was defined by the absence of neurological symptoms throughout the disease course. Type 2 GD (acute infantile neuronopathic) and type 3 GD (chronic neuronopathic) were based on the age at which neurological signs and symptoms first manifested, and the rate of progression. Type 2 GD presents with neurological symptoms that appear within the first few months of life and progress rapidly, often resulting in severe degeneration and mortality in infancy or early childhood. Type 3 GD is typically associated with a variety of symptoms, including visceral involvement, oculomotor apraxia, and, in some instances, bulbar signs such as stridor, strabismus, feeding difficulties, epilepsy, ataxia, or dementia [10].
β-Glucosidase enzyme assay
The β-Glucosidase enzyme assay was conducted using tandem mass spectrometry on dried blood spots. Enzyme activity levels were considered reduced if below the cut-off value of 1.5 µmol/L/h.
Anzeige
Single-gene sequencing (GBA1 gene)
DNA was extracted from dried blood spot samples. Polymerase Chain Reaction (PCR) amplification and sequencing were performed for all coding exons and flanking intronic regions of the GBA1 gene. The sequences were aligned to the reference sequence NM_000157.3 (ENST00000368373) at the international medical laboratory Archimed Life. Detected variants were described according to the Human Genome Variation Society (HGVS) recommendations for the description of sequence variants (2016 update: Hum Mutat. 2016 Jun;37(6):564-9) [11].
Results
Sixty-eight patients (45 males and 23 females) participated in this study. Patient ages ranged from 5 months to 58 years, with a median age of 21 years. The age at diagnosis ranged from 4 months to 57 years. All patients exhibited reduced or absent β-glucocerebrosidase activity, accompanied by clinical manifestations consistent with GD. The demographic data of the patients are presented in Table 1. Thirty patients (44.1%) were classified as type 1 GD, with a mean age of 8.93 ± 13.66 years. A positive family history was noted in 21 patients (70%), and 23 patients (77.3%) reported parental consanguinity. Type 2 GD was identified in three patients, all of whom unfortunately died before reaching the age of 2 years. Type 3 GD was the most prevalent form, identified in 35 patients (51.5%), with a consanguinity rate of 28 patients (80%).
Table 1
Demographic, clinical, and biochemical data of our cohort
Type 1 | Type 2 | Type 3 | |
|---|---|---|---|
n (%) | 30 (44.1) | 3 (4.4) | 35 (51.5) |
Gender, n (%) | |||
Male Female | 20 (66.7) 10 (33.3) | 2 (66.7) 1 (33.3) | 23 (65.7) 12 (36.3) |
Age at diagnosis (years) | |||
Mean ± SD Median (min-max) | 8.93 ± 13.66 4.35 (0.9–57) | 0.9 ± 0.1 0.9 (0.8-1) | 2.3 ± 1.8 1.85 (0.5–10.3) |
Current age (years) | |||
Mean ± SD Median (min-max) | 11.11 ± 12.38 8.15 (2.3–58) | --- --- | 6.7 ± 5.8 5.1 (1.4–17.1) |
Presenting Manifestations | Hepatosplenomegaly, Bone involvement, Thrombocytopenia, Pancytopenia, Leucopenia, Anemia | Hepatosplenomegaly, Progressive CNs involvement in the form of strabismus, bulbar signs, spasticity refractory Epilepsy | Hepatosplenomegaly, Cytopenia, Cognitive problems, Developmental delays, Eye movement disorders, Poor coordination, Seizures |
Positive Family history, n (%) | 21 (70.0) | 1 (33.3) | 17 (48.5) |
Consanguinity | 23 (77.3) | 2 (66.7) | 28 (80) |
Dead, n (%) | 0 (0.0) | 3 (100.0) | 2 (5.7) |
Age of death (years) | & | € | |
--- --- | 1.6 1.8 1.4 | 12.8 8.5 | |
β-Glucosidase activity | |||
Mean (SD) Median (Range) | 0.37 ± 0.30 0.3 (0.1–1.2) | 0.23 ± 0.13 0.2 (0.1–0.5) | 0.24 ± 0.17 0.2 (0.0–0.8) |
Lyso-GL-1 Mean (SD) Median (Range) | 1289.26 ± 1241.24 877 (450–5504) | 1230.58 ± 763.86 994 (261–2584) | 1196.12 ± 968.18 1000 (450–5485) |
Pathogenic variants and types detected in the studied group
A total of 136 alleles from 68 patients across 47 independent families were analyzed. The most prevalent variant was c.1448T > C p.(Leu483Pro), accounting for 50.7% (n = 69) of all mutant alleles. In contrast, the c.1226 A > G p.(Asn409Ser) variant represented 7.35% (n = 10) of the identified mutant alleles. Among the identified variants, 128 (94%) were missense, 2 (1.5%) were nonsense variants, and 6 (4.4%) were recombinant alleles (Table 2).
Table 2
Variants and allele frequencies in the studied group (68 patients, 136 alleles, from 47 independent families). All variants were described according to NM_000157.4 (GBA transcript) and NP_000148.2 (GBA protein)
Transcript | Protein | Molecular Consequence | Classification | Allele Frequency n (%) |
|---|---|---|---|---|
c.1448T > C | p.Leu483Pro | Missense | Pathogenic | 69 (50.7) |
c.1226 A > G | p.Asn409Ser | Missense | Pathogenic/likely pathogenic | 10 (7.35) |
*c.263 C > T | p.Met88Thr | Missense | Pathogenic | 8 (5.88) |
*c.1331 A > G | p.Asp444Gly | Missense | Pathogenic | 8 (5.88) |
*c.1409 C > T | p.Ser470Phe | Missense | Pathogenic | 6 (4.4) |
c.710 A > C | p.Lys237Thr | Missense | Pathogenic | 5 (3.67) |
c.1604G > A | p.Arg535His | Missense | Pathogenic/Likely pathogenic | 5 (3.67) |
c.847T > C | p.Tyr283His | Missense | Likely pathogenic | 4 (2.9) |
1265_1319del55+1448T > C;1483G > C;1497G > C | Recombinant allele | Pathogenic | 4 (2.9) | |
c.1342G > C | p.Asp448His | Missense | Pathogenic/Likely pathogenic | 2 (1.47) |
*c.907 C > G | p.Leu303Val | Missense | Pathogenic | 2 (1.47) |
c.1193G > A | :p.Arg398Gln | Missense | Pathogenic/Likely pathogenic | 2 (1.47) |
c.475 C > T | p.Arg159Trp | Missense | Pathogenic | 2 (1.47) |
c.680 A > G | :p.Asn227Ser | Missense | Pathogenic | 2 (1.47) |
*c.1574G > A | p.Gly525Asp | Missense | Pathogenic | 2 (1.47) |
*c.380 C > G | p.Ala127Gly | Missense | Pathogenic | 1 (0.7) |
c.754T > A | p.Phe252lle | Missense | Pathogenic/Likely pathogenic | 1 (0.7) |
*c.453 + 2T > C | – | Splice Site | Pathogenic | 1 (0.7) |
We documented seven novel variants within the cohort (Table 2). The first variant, c.263 C > T p.(Met88Thr), was a homozygous missense variant observed in four patients (5.88%) from a single family (three boys and one girl). The symptoms first appeared in the eldest sibling at the age of five years with anemia and hepatosplenomegaly. Subsequent screening of family members led to the identification of the remaining cases. The second novel variant, c.1331 A > G p.(Asp444Gly), was also a homozygous missense variant found in four patients across two families. Three patients (two boys and one girl) belonged to the same family and were diagnosed at the ages of 10, 7, and 4 years with symptoms, including hepatosplenomegaly and bleeding of varying severity. The eldest sibling suffered from severe bone pain with a history of right femur fracture (Table 1).
The third variant, c.1409 C > T p.(Ser470Phe), was a homozygous missense variant identified in three patients (4.4%) from three different families. All three patients presented with anemia, hepatosplenomegaly, and easy bruising. The fourth, c.907 C > G p.(Leu303Val), and fifth, c.1574G > A p.(Gly525Asp), variants were identified as missense variants in a single patient. The sixth, c.380 C > G, p.(Ala127Gly), was a heterozygous missense variant detected in a 2-year-old girl presenting with hepatosplenomegaly with stunted growth. The seventh, [453 + 2T > C], was a heterozygous missense variant identified in a 23-year-old female with splenomegaly and thrombocytopenia associated with heavy menstrual bleeding. All patients carrying these novel variants displayed low enzyme activity and clinical manifestations consistent with type 1 GD, as none developed neurological signs throughout the disease course (Table 3).
Table 3
Genotype-phenotype correlation of the studied group (All variants were described according to NM_000157.4 (GBA transcript) and NP_000148.2 (GBA protein))
No. of patients | No. of families | Allele 1 | Allele 2 | No. of Patients/Phenotype | Frequency | ||
|---|---|---|---|---|---|---|---|
Type I | Type 2 | Type 3 | |||||
31 | # 21 | c.1448T > C, p.Leu483Pro | c.1448T > C, p.Leu483Pro | - | 3 | 28 | 45.58% |
4 | #3 | c.1448T > C, p.Leu483Pro | 1265_1319del55+1448T > C;1483G > C;1497G > C | 4 | 5.88% | ||
4 | &2 | c.1226 A > G, :p.Asn409Ser | c.1226 A > G, :p.Asn409Ser | 4 | 5.88% | ||
4 | &1 | *c.263 C > T, p. p.Met88Thr | *c.263 C > T, p. p.Met88Thr | 4 | 5.88% | ||
4 | $2 | *c.1331 A > G, p. Asp444Gly | *c.1331 A > G, p. Asp444Gly | 4 | 5.88% | ||
3 | &3 | *c.1409 C > T, p.Ser470Phe | *c.1409 C > T, p.Ser470Phe | 3 | 4.4% | ||
1 | &1 | c.1448T > C, p.Leu483Pro | *c.1574G > A, p.Gly525Asp | 1 | 2.9% | ||
2 | $2 | c.847T > C, p.Tyr283His | c.847T > C, p.Tyr283His | 2 | 2.9% | ||
2 | &1 | c.1604G > A, p.Arg535His | c.1604G > A, p.Arg535His | 2 | 2.9% | ||
2 | &1 | c.475 C > T, p.Arg159Trp | c.680 A > G, :p.Asn227Ser | 2 | 2.9% | ||
2 | &1 | c.710 A > C, 710 A > C, p.Lys237Thr | :c.710 A > C, p.Lys237Thr | 2 | 2.9% | ||
1 | 1 | c.710 A > C, p.Lys237Thr | c.475 C > T, p.Arg159Trp | 1 | 1.47% | ||
1 | &1 | c.1448T > C, p.Leu483Pro | c.1604G > A, p.Arg535His | 1 | 1.47% | ||
1 | 1 | c.1448T > C, p.Leu483Pro | c.1226 A > G, :p.Asn409Ser | 1 | 1.47% | ||
1 | &1 | c.1193G > A, p.Arg398Gln | c.1193G > A, p.Arg398Gln | 1 | 1.47% | ||
1 | 1 | *c.907 C > G, p.Leu303Val | *c.907 C > G, :p.Leu303Val | 1 | 1.47% | ||
1 | &1 | c.1342G > C, p.Asp448His | c.1342G > C, p.Asp448His | 1 | 1.47% | ||
1 | &1 | c.1226 A > G, :p.Asn409Ser | *c.453 + 2T > C | 1 | 1.47% | ||
1 | &1 | c.1448T > C, p.Leu483Pro | *c.380 C > G, p.Ala127Gly | 1 | 1.47% | ||
1 | &1 | c 1342G > C (p Asp448His) | c 1342G > C (p Asp448His) | 1 | 1.47% | ||
Anzeige
Phenotype /genotype correlation
Homozygous variants
Eleven homozygous GBA1 gene variants were identified among fifty-five patients (Table 3). The most prevalent variant was c.1448T > C p.(Leu483Pro), which was found in 31 patients (45.58%). Among these, 28 patients were phenotypically classified as type 3 GD (chronic neuronopathic) due to the late onset of neurological symptoms. The remaining three patients exhibited features of type 2 GD (acute neuronopathic), characterized by progressive central nervous system involvement, including strabismus, bulbar signs, and spasticity, leading to early mortality before two years of age (Table 1). The homozygous variant c.710 A > C p.(Lys237Thr) was detected in two patients (2.94%), both phenotypically categorized as type 3 GD. Additionally, nine different homozygous GBA1 gene variants were observed in 22 patients, all of whom showed no neurological signs throughout the disease course and were thus classified as type 1 GD (Table 3).
Compound heterozygous
Thirteen patients were found to have compound heterozygous GBA1 gene variants. The most frequently observed compound variant was c.1448T > Cp.(Leu483Pro)/1265_1319del55;1448T > C;1483G > C;1497G > C, identified in four patients who exhibited a range of symptoms, including visceral and chronic neurological involvement (type 3 GD). An additional compound heterozygous variant, c.710 A > C p.(Lys237Thr)/c.754T > A p.(Phe252lle), was identified in a single patient whose clinical manifestations were consistent with type 3 GD. The remaining eight patients were phenotypically classified as type 1 GD and carried six different compound heterozygous variants (Table 3).
Discussion
In this study, we describe the clinical characteristics and GBA1 variant spectrum of 68 patients with GD from Upper (southern) Egypt, all of whom received GD-specific enzyme replacement therapy, imiglucerase (Cerezyme®), at the hematology units of Assiut and Ain Shams University Children’s Hospitals. GD exhibits significant heterogeneity in both clinical manifestations and genetic variation, a phenomenon evident in our patient cohort. Clinically, patients exhibited a wide range of phenotypes associated with GD; 30 patients (44.1%) were classified as type 1, 3 patients (4.4%) as type 2, and 35 patients (51.5%) as type 3. Among those with the most severe manifestations, we identified patients with progressive central nervous system involvement, with fatalities occurring as early as 1.5 years of age. At the other end of the spectrum, we identified a patient with mild disease diagnosed at the age of 57 years after the detection of GD in family members. The former patient was homozygous for c.1448T > C p.(Leu483Pro), whereas the latter was homozygous for c.1226 A > G p.(Asn409Ser), a variant often associated with very mild disease.
Although GD is an autosomal recessive disease, we observed a male predominance with a 2:1 ratio. This is consistent with previous Egyptian studies that reflect cultural behavior in Upper Egypt, where males receive greater medical care and attention [12]. In Upper Egypt, GD is the most diagnosed sphingolipidosis and the second most common lysosomal storage disease after mucopolysaccharidoses. It results from biallelic pathogenic variants in the GBA1 gene, located on chromosome 1q21, which comprises 11 exons [13]. More than 700 distinct GBA1 variants have been reported globally, with distribution varying significantly by population [14]. The most common variants worldwide include c.1226 A > G p.(Asn409Ser) (previously N370S); c.1448 T > C p.(Leu483Pro) (previously L444P); c.115 + 1G > A (previously IVS2 + 1G > A); and c.84dupG p.(Leu29AlafsTer18) (previously 84 GG [84-85insG]) [15].
The results of this study show that the most frequent GBA1 variant was c.1448T > C p.(Leu483Pro) (50.7%), followed by c.1226 A > G p.(Asn409Ser) (7.35%), matching other Egyptian studies that reported the c.1448T > C variant in 50–60% of cases [16, 17]. Our findings also align with studies from Turkey, Iran, and the JAPAC region (China, India, Japan, Korea, Malaysia, and the Philippines) [18‐22]; however, some populations report lower prevalences ranging between 18.5% and 25% [7, 23, 24]. In European, American, Brazilian, Venezuelan, and Jewish populations, c.1226 A > G p.(Asn409Ser) is the most frequently reported variant [25‐28]. Thus, c.1226 A > G variant prevalence declines from west to east, whereas the prevalence of the c.1448T > C p.(Leu483Pro) variant increases in the same direction.
In our study, the pathogenic c.1448T > C p.(Leu483Pro) variant was detected in both homozygous and compound heterozygous forms, with frequencies of 45.8% and 10.3%, respectively. In the homozygous state, this variant was associated with type 2 (3/3; 100%) and type 3 (28/35; 80%) phenotypes. Among patients with type 1 GD, c.1448T > C appeared in a heterozygous combination with c.1226 A > G p.(Asn409Ser), c.1604G > A p.(Arg535His), and c.380 C > G p.( Ala127Gly) in 3 out of 30 cases (10%). These patients require close monitoring due to their subtle course and potential late neurological manifestations.
Anzeige
Genotype–phenotype correlation in GD is not absolute. In our study, several patients homozygous for c.1448T > C were initially diagnosed as type I GD based on early presentations of hepatosplenomegaly and cytopenia without neurological manifestations. However, with long-term follow-up, these patients developed supranuclear gaze palsy and cognitive impairment, prompting reclassification to type 3 GD. This occurred despite ongoing enzyme replacement therapy, which appeared to delay, but did not prevent neurological progression [17]. Conversely, some patients initially classified as type 3 based on neurological involvement were reclassified to type 2 due to rapid clinical deterioration and early mortality. Notably, survival beyond two years is atypical for classical type 2 GD. While the homozygous L444P mutation is traditionally linked to Type 3 Gaucher disease [12], our study shows that, in uncommon instances it could lead to a phenotype resembling Type 2, possibly as a result of unidentified genetic modifiers or hidden variants [29]. Additional genomic and functional investigations are necessary to clarify the mechanisms underlying this unusual severity.
Despite having the neuropathic GBA1 genotype, Egyptian patients with type 3 GD often exhibit a milder phenotype and improved outcomes with enzyme replacement therapy, suggesting potential modifying genes that enhance prognosis following treatment [30‐32]. However, not all patients with neuropathic GD carry the c.1448T > C p.(Leu483Pro) variant. In our study, we identified two known variants associated with type 3 GD. The c.710 A > C p.(Lys237Thr) variant, one of the most common variants globally, was found in two patients in the homozygous state, and in one patient in compound heterozygosity with c.754T > A p.(Phe252lle). The latter is a unique pathogenic variant in Asian populations and has been reported in three neuronopathic GD patients in Morocco [33, 34].
The second GAB1 variant identified in this study was the missense c.1226 A > G p.(Asn409Ser) variant. It was detected in four patients in the homozygous state and in two patients in the heterozygous state, all of whom were diagnosed with GD type 1 without neurological involvement. The frequency of this variant is consistent with previous Egyptian studies, which reported it in 8.7% of 195 patients (34 alleles out of 390) [12]. The c.1226 A > G p.(Asn409Ser) variant is prevalent among Ashkenazi Jews, comprising 75–80% of alleles; however, it is rare or absent in populations such as the Japanese [8, 35, 36]. This variant is considered neuroprotective, being exclusive to type 1 patients. The compound heterozygous variant c.1448T > C p.(Leu483Pro)/c.1226 A > G p.(Asn409Ser) was found in one patient. The two alleles are rarely found together in Egyptian cohorts, except for isolated cases reported by Khalifa et al. [17] and Fateen et al. [12]. In contrast, this genotype is more frequent in Spanish and Portuguese populations [37].
This study detected known GBA1 homozygous variants: c.847T > C p.(Tyr283His) and c.1604G > A p.(Arg535His), detected in two patients each, and c.1193G > A p.(Arg398Gln) and c.1342G > C p.(Asp448His), detected in one patient each. Additionally, c.475 C > T p.(Arg159Trp) and c.680 A > G p.(Asn227Ser) was detected in two patients as compound heterozygous variants. All these variants were detected in type 1 GD patients and were previously reported in the literature. Furthermore, our study identified two different recombinant alleles in six of our patients (4.4% of total alleles and 8.8% of patients). To date, over 20 recombinant GBA1 alleles have been identified, with RecNcil and Recdelta55 being most prevalent, either alone or in conjunction with other point variants [38, 39]. RecNcil originates from a cross-over between intron 9 and exon 10, leading to the incorporation of a C.P1 segment into the functional GBA1 gene, including the missense variants c.1448 T > C p.(L483P), c.1483G > C p.(A495P), and c.1497G > C p.(V499 V). Recdelta55 [c.1265_1319del p.(Leu422fs)] involves a 55-bp deletion in exon 9 of the GBA1 gene, corresponding to the deleted portion of the pseudogene [40]. Recombinant alleles that include the 55-bp deletion in exon 9 were reported with other point variants or with RecNcil [41, 42].
Anzeige
In our study, the recombinant variant RecNcil (c.1574G > A/RecNcil) was identified in a compound heterozygous state in two patients with type 1 GD. Interestingly, a complex and rare variant resulting from the recombination of Rec1263del55 and RecNcil alleles was identified in four patients (5.88%) with type 3 GD in a compound heterozygous form with c.1448T > C p.(Leu483Pro) [40]. Nevertheless, these patients exhibit phenotypic heterogeneity. The frequency of recombinant alleles (Rec) in our study was lower than previously reported rates, which include 38.1% in Egyptian patients with type 1 GD [16], and 9.5–21% reported in other international studies [23, 43].
Our study identified known GBA1 variants such as c.847T > C p.(Tyr283His), c.1604G > A p.(Arg535His), each in two patients, and c.1193G > A p.(Arg398Gln), c 1342G > C (p Asp448Hs); each in one patient, all were homozygous. Additionally, c.475 C > T p.(Arg159Trp) and c.680 A > G p.(Asn227Ser) were identified in two patients as compound heterozygous variants. All variants were identified in type 1 GD patients, as previously documented in the literature. In addition, our study revealed seven novel variants in 22% of our cohort: c.263 C > T p.(Met88Thr) and c.1331 A > G p.(Asp444Gly) each in four homozygous patients; c.1409 C > T p.(Ser470Phe) in three patients; and c.907 C > G p.(Leu303Val) in one patient, all in homozygous form. The remaining variants, c.1574G > A p.(Gly525Asp) and c.380 C > G p.(Ala127Gly), were each found in one patient as compound heterozygous variants along with the other known variants. All patients carrying these novel variants exhibited reduced enzyme levels and clinical symptoms characteristic of type 1 GD, without neurological signs during disease progression. None of these variants have been previously reported in PubMed or publicly available databases such as ClinVar, HGMD, or dbSNP.
In addition, a splice-site variant, c.453 + 2T > C in intron 4, was identified and located within the intronic regions. Although its exact protein has not been determined, it may be disease-related due to a splicing alteration. This variant was detected in a 22-year-old female patient with type 1 GD, in heterozygosity with c.1226 A > G p.(Asn409Ser). We found a high rate of consanguinity (77.9%) in our cohort, resulting in the high frequency of homozygous variants (80%). The Middle East, particularly Upper Egypt, has some of the world’s highest consanguinity rates (21–33%), contributing to elevated homozygosity even among non-related couples in rural communities due to the long-standing national traditions [44].
Conclusion
In conclusion, this study presents the findings of 68 patients with GD from Upper Egypt, covering the entire spectrum of disease phenotypes. Analysis of the 136 mutant alleles identified 19 different variants (including 7 novel variants) and 19 genotypes. The c.1448T > C p.(Leu483Pro) variant was the most prevalent (50.7%), with the homozygous form representing the most common genotype (45.5%). Genotype–phenotype correlations confirmed that the c.1226 A > G p.(Asn409Ser) variant is not associated with the development of neurological complications, whereas the c.1448T > C p.(Leu483Pro) variant was strongly linked to severe neuronopathic phenotypes (types 2 and 3 GD). The distribution of mutant alleles and the frequency of specific genotypes exhibit distinct characteristics that may reflect the ethnic features of our community. Identifying these variants expands the understanding of the global GBA1 variant landscape, provides insights into the disease’s molecular basis, establishes genotype–phenotype correlations, supports genetic counseling, and performs customized molecular analyses for families at risk.
Acknowledgements
We express our gratitude to the General Administration for Reducing Genetic Diseases and Disabilities, Ministry of Health, for supplying ERT in centers of excellence for Gaucher disease in Egyptian universities, which greatly contributed to our research. We thank the international medical laboratory Archimed Life for conducting the β-Glucosidase enzyme assay and GAB1 gene sequencing for all patients enrolled in this study.
Declarations
Ethical Statement
This study was conducted in accordance with the tenets of the Declaration of Helsinki 1964. The study was approved by Assiut University’s Ethical Committee for Clinical Research (approval number: 04-2023-300227). Signed statements of informed consent to participation and publication were obtained from the guardians of trial participants before the study. The consent requirement was waived for retrospective participants by the above-named ethics committee.
Competing interests
The authors declare no competing interests.
Conflict of interest
None of the authors has any potential conflict of interest to declare.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
